AR and prostate carcinoma: Additional studies on prostate cancer have demonstrated that the m6A-modified androgen receptor (AR) mRNA phase separated with YTHDF3, while the unmodified AR mRNA phase separated with G3BP1 to survive AR pathway inhibition stress (Fig. 4L)[186].